Coversyl shown to reduce mortality rate

The ACE inhibitor Coversyl (perindopril) has been approved for the treatment of stable coronary artery disease to reduce the risk of cardiac events in patients with a history of myocardial infarction and/or revascularisation.

The change to the licensed indications for Coversyl was made on the basis of results from a major, four-year, double-blind study involving over 12,000 patients with stable coronary artery disease and without heart failure or substantial hypertension.

The study showed that Coversyl 8 mg once daily reduced the combined risk of cardiovascular mortality, non-fatal myocardial infarction and cardiac arrest. The benefits were obtained on top of other preventative medications such as anti-platelet agents, lipid- lowering drugs and ß-blockers, and were consistent for all coronary artery disease patients irrespective of age or other cardiac risk factors.

For adults with stable coronary artery disease, treatment should be initiated at a dose of 4 mg once daily for two weeks, before increasing to 8 mg once daily.

In elderly patients, the dose should be started at 2 mg once daily, increasing after one week to 4 mg once daily for the next week, before increasing to 8 mg once daily.

In all patients, dose titration is dependent upon tolerance and renal function.

Further information: Servier Laboratories Ltd, Gallions, Wexham Springs, Framewood Road, Slough, Berks, SL3 6RJ. Tel: 01753 662744.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more